Peer-influenced content. Sources you trust. No registration required. This is HCN.
According to the FDA, Phesgo — the combination of pertuzumab, trastuzumab and hyaluronidase-zzxf – is initially used in combination with chemotherapy and then can be administered subcutaneously at home by a health care professional after completion of chemotherapy.
Internal Medicine July 6th 2020
Gastrointestinal and breast cancer sessions were featured on the first day of the virtual conference, highlighting practice-changing results from a multitude of studies, including the HER2CLIMB, MINDACT, and PHERGAIN trials.
Gastroenterology June 8th 2020
According to study results presented at ASCO20 Virtual Scientific Program, a year of maintenance therapy with metronomic capecitabine after standard treatment extended DFS among women with operable triple-negative breast cancer.
Hematology June 1st 2020
According to a study featured in the Journal of Clinical Oncology, pre-surgery letrozole led to significant imaging and biomarker changes in postmenopausal patients with estrogen receptor (ER)-positive ductal carcinoma in situ (DCIS) in a phase 2 clinical trial.
Internal Medicine May 11th 2020